Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 July 2007, Vol. 110, No. 1, pp. 388-392.
Prepublished online as a Blood First Edition Paper on March 14, 2007; DOI 10.1182/blood-2006-12-064816.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables and Figures
Right arrow All Versions of this Article:
blood-2006-12-064816v1
110/1/388    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dik, W. A.
Right arrow Articles by Langerak, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dik, W. A.
Right arrow Articles by Langerak, A. W.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Brief Reports
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Brief Report

Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL

Willem A. Dik1, Bertrand Nadel2, Grzegorz K. Przybylski3,4, Vahid Asnafi5, Piotr Grabarczyk4, Jean Marc Navarro2, Brenda Verhaaf1, Christian A. Schmidt4, Elizabeth A. Macintyre5, Jacques J. M. van Dongen1, and Anton W. Langerak1

1 Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands; 2 Centre d'Immunologie de Marseille-Luminy (CIML), Institute Nationale de Santé et Recherche Médicale-Centre Nationale de Recherche Scientifique (INSERM-CNRS)-Université de la Méditerranée, Marseille, France; 3 Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland; 4 Klinik für Innere Medizin C, Universität Greifswald, Germany; 5 Department of Hematology, Université Paris-Descartes, Faculté de Médecine, Hôpital Necker-Enfants-Malades, Paris, France

The t(11;14)(p13;q11) is presumed to arise from an erroneous T-cell receptor delta TCRD V(D)J recombination and to result in LMO2 activation. However, the mechanisms underlying this translocation and the resulting LMO2 activation are poorly defined. We performed combined in vivo, ex vivo, and in silico analyses on 9 new t(11;14)(p13;q11)-positive T-cell acute lymphoblastic leukemia (T-ALL) as well as normal thymocytes. Our data support the involvement of 2 distinct t(11;14)(p13;q11) V(D)J-related translocation mechanisms. We provide compelling evidence that removal of a negative regulatory element from the LMO2 locus, rather than juxtaposition to the TCRD enhancer, is the main determinant for LMO2 activation in the majority of t(11;14)(p13;q11) translocations. Furthermore, the position of the LMO2 breakpoints in T-ALL in the light of the occurrence of TCRD-LMO2 translocations in normal thymocytes points to a critical role for the exact breakpoint location in determining LMO2 activation levels and the consequent pressure for T-ALL development.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. A. Khan, D. Susa, J. W. van den Berg, M. Huisman, M. H. Ameling, S. van den Engel, H. P. Roest, J. N. M. IJzermans, W. A. Dik, R. Benner, et al.
Amelioration of renal ischaemia-reperfusion injury by synthetic oligopeptides related to human chorionic gonadotropin
Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2701 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
L. van Steensel, D. Paridaens, B. Schrijver, G. M. Dingjan, P. L. A. van Daele, P. M. van Hagen, W. A. van den Bosch, H. A. Drexhage, H. Hooijkaas, and W. A. Dik
Imatinib Mesylate and AMN107 Inhibit PDGF-Signaling in Orbital Fibroblasts: A Potential Treatment for Graves' Ophthalmopathy
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3091 - 3098.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
A. Bagg
Malleable Immunoglobulin Genes and Hematopathology - The Good, the Bad, and the Ugly: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn., September 1, 2008; 10(5): 396 - 410.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020